These data show that 30% of the adult population in the United States has [sleep apnea](https://www.withpower.com/clinical-trials/sleep-apnea). In the United States, the sleep problem will worsen in one of eight respondents in every one hundred and twenty four. It implies a significant impact on a society's health.
In a cohort of US adults, we identified factors associated with sleep disturbances and identified potential factors for consideration when assessing sleep disturbance on the Brief International Classification of Sleep Disorders (BISD). These factors can be useful in the identification of individuals needing sleep intervention for sleep disorders and for optimizing sleep quality. Findings from a recent study suggest an association between the burden of chronic disease, obesity, medical conditions, and depression with increased symptom severity of sleep-based disordered breathing and nonrestorative sleep.
There is a clear biological basis for sleeplessness as a symptom with many possible causes, but this does not account for the fact that one-quarter of adults report they never have a full night's sleep. More work is needed on biological explanations and the implications of this in order to investigate the ways this may be resolved to support sleep hygiene practices.
Sleeplessness is considered to be a symptom or consequence of mental illness in many, but not all, languages. Most languages have specific terminology for sleeplessness. However, in some languages, such as Arabic, there are very few terms for sleeplessness. For example, no single term is used for sleeplessness but there are two terms specifically related to sleeplessness, 'tire' and 'drear' (e.g., 'tirey' or 'dreary' refers to sleeplessness).
Sleeping problems are treated with different techniques. Most often, no medications are prescribed. In the case of insomnia, medications are prescribed. The use of certain medications is not always adequate to treat sleep or insomnia symptomatology because the effect of a specific patient may not be predicted. These recommendations are based on data from a few trials about the management of sleep or insomnia. More data are needed to address the question of what is an adequate treatment.
We report one case of suicide in a man with BBTI, suggesting that patients remain at risk for suicide even if they successfully complete treatment. Further research is warranted to evaluate the long-term outcomes and to examine risk factors for suicide in BBTI patients.
According to these findings, patients may have a more severe response to treatment for sleep problems than to placebo. A higher percentage of patients with SES 2 (SQS 2) reported that their sleep quality improved more with nCPAP use than with placebo. Patients with SES 0 (SQS 0) reported that the use of nCPAP was not helpful for their sleep quality at either the nCPAP or the placebo group. NCPAP use was not helpful for patients with SES 1 (SQS 1) to sleep quality.
In a recent study, findings point out the need for more research, to evaluate the long-term (6-months) efficacy of bbti, the most successful method presently used for the treatment in primary insomnia, among patients who are unwilling to accept medication therapy.
The data suggest that sleep deprivation may have some adverse effects on cognitive abilities that depend on adequate neural systems related to the sleep system. Further studies are necessary to better evaluate the adverse effects of sleepiness.
Results suggest that brief behavioral therapy for insomnia (bbti), specifically designed to treat insomnia, is a valuable intervention. A more thorough description of the BDT, as well as more rigorous controls for attrition within the BDT, is needed.
The improvements seen in most of the participants were seen regardless of whether or not they had an active diagnosis of insomnia. Moreover, they were mostly short-lasting. Results from a recent clinical trial support the use of this brief intervention for sleep problems in primary care, but do not support the use of this technique as a treatment for insomnia.